Preliminary results from the first descriptive study of co-administration of the high-dose quadrivalent vaccine of Sanofi Pasteur with the third dose of Covid-19 mRNA vaccine show that co-administration of the two vaccines was safe, well tolerated and with an adequate antibody response. equal to each vaccine administered individually. This is what we read in a note from the company, which recalls that “the high-dose quadrivalent flu vaccine is indicated in adults from 60 years of age in Italy. It is the only flu vaccine – recalls Sanofi Pasteur – that has demonstrated superior efficacy in the prevention of laboratory-confirmed influenza disease and the reduction of complications associated with influenza, such as hospitalizations for cardiovascular events and pneumonia, for 10 consecutive seasons in more than 34 million people “.
The encouraging results of the co-administration study – underlines the note – reinforce the recommendations for the simultaneous administration of the two vaccines also in Italy. “This study demonstrates how in an unprecedented historical period like the one we are experiencing, still marked by the health emergency of the pandemic and with the new flu season at the door, we need timely, rapid and concrete answers on the optimal and effective management of campaigns. vaccination “, says Francesca Trippi, Medical Head of Sanofi Pasteur.
“This – continues Trippi – is the first study that has made it possible to produce positive scientific evidence in terms of antibody responses and safety profile, supporting the concomitant administration of the high-dose influenza vaccine with the third dose of Covid-19 vaccine. . These results go in the direction of facilitating the carrying out of vaccination campaigns in order to guarantee optimal protection for the high-risk population “.
“Never before this season is it even more essential to help protect older adults, who are at particularly high risk for both Covid-19 and influenza complications, which can include heart attacks and strokes,” says Michael Greenberg. , Chief Medical Officer Sanofi Pasteur North America. “This is the first study to provide evidence to support influenza vaccination in conjunction with a Covid-19 mRNA booster in the elderly. These positive results could facilitate the implementation of influenza vaccination campaigns and Covid booster. in the Northern Hemisphere, especially in this high-risk segment of the population. “
The descriptive study – the note details – was conducted in the United States and enrolled about 300 participants who received two doses of a Covid-19 mRNA vaccine as their primary vaccination at least five months prior to enrollment. The study assesses the safety profile and immune response following coadministration of the third dose of Covid-19 mRNA vaccine (100 mcg dose) with the high-dose quadrivalent influenza vaccine. The full results of the study will be published later in the year. The study is sponsored by Sanofi, in partnership with the Biomedical Advanced Research and Development Authority (Barda), part of the Office of the U.S. Department of Health and Human Services Assistant Secretary for Preparation and Response, and with Moderna .